AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04448028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with a pre-existing PPI therapy discontinue PPI therapy and replace it with placebo over a period of 346 days after a 14 day dose tapering phase.
Study NCT04448028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 20mg
Description: Patients with a pre-existing PPI therapy stop their prior PPI medication and have it replaced with esomeprazole 20mg/day for 360 days.
Study NCT04448028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esomeprazole 20mg
Description: Patients with a pre-existing PPI therapy stop their prior PPI medication and have it replaced with esomeprazole 20mg/day for 360 days.
Study NCT05328557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUG252
Description: CUG252 will be administered by subcutaneous (SC) injection
Study NCT05328557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by subcutaneous (SC) injection
Study NCT06319950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib, 160mg po qd
Study NCT06205849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRE + intratumoral mitazalimab (CD40 antibody) injection
Description: Surgical IRE will be performed using the NanoKnife System with intraoperative ultrasound guidance via laparotomy under general anesthesia. Mitazalimab (CD40 antibody) will be administered 5 minutes after completion of IRE by slow injection into the center of the ablated zone using a small needle. Core needle biopsies of the tumor will be obtained immediately prior to IRE for identification of candidate tumor antigens. Peripheral blood will be obtained immediately prior to and 12 weeks after the study intervention for analysis of systemic immune effects.
Study NCT06205849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Description: Non-thermal tumor ablation using short pulses of high voltage electrical current delivered using 19-gauge needles placed via laparotomy using ultrasound guidance
Study NCT05122637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RapidPulseTM Aspiration System
Description: The RapidPulseTM Aspiration System with Medtronic React 71 aspiration catheter and a commercially available pump.
Study NCT05122637 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard of Care Aspiration Thrombectomy System
Description: Commercially available aspiration catheter with commercially available aspiration pump
Study NCT05254028 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: filiform needle
Description: Manual acupuncture using filiform needles
Study NCT05125250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Control Group
Description: will received treatment which comprises of therapeutic exercises, During the first 4 weeks, motor control and ROM exercises will be prescribed in order to improve muscular endurance of deep flexors muscles and to improve the ROM of cervical spine in flexion, extension, rotation and side bending and lateral rotation in. These exercises will be performed at a rate of 3 sets and an intensity of 15 repetitions per day .
Study NCT05125250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Group
Description: will receive vestibular exercises which comprises of postural awareness training, balance board exercises, Foveal vision exercises .
Study NCT05155254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IO102-IO103
Description: IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously
Study NCT05155254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously
Study NCT05155254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously
Study NCT06205108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS stimulation
Description: Non-invasive stimulation of the auricular branch of the vagus nerve (cymba conchae). Research device from tVNS technologies.
Study NCT06205108 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: Non-invasive stimulation of the ear lob (not innervated by the vagus nerve). Research device from tVNS technologies.
Study NCT06319950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib，80mg po qd
Study NCT05358613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Choices
Description: The My Choices program is an harm reduction program to modify substance use habits. It is based on the Miller \& Rollnick Motivational interviewing as well as Deci and Ryan's Self-determination theory and Bandura's social learning theory.~It is presented as a guide, divided in 6 phases. In every phase, participants will find, in the guide, some auto-observation exercises about their alcohol use habits and other aspects about their quality of life, reflexions and information about alcohol. The participants are also invited to note the number of standard units of alcohol they use on every occasion.
Study NCT05358613 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Choices
Description: The My Choices program is an harm reduction program to modify substance use habits. It is based on the Miller \& Rollnick Motivational interviewing as well as Deci and Ryan's Self-determination theory and Bandura's social learning theory.~It is presented as a guide, divided in 6 phases. In every phase, participants will find, in the guide, some auto-observation exercises about their alcohol use habits and other aspects about their quality of life, reflexions and information about alcohol. The participants are also invited to note the number of standard units of alcohol they use on every occasion.
Study NCT04790565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: Fecal microbiota in frozen capsules
Study NCT05901753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryseal pro supra glottic device
Description: The laryseal pro SP will be advanced at a forward angle aiming for the back of the tongue and soft palate. Then the colored connector will be pushed by index finger till feeling resistance . Device insertion will be considered successful by observing bilateral chest wall movement as well as a stable square-wave capnogram trace
Study NCT05901753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway- Proseal™
Description: The cuff will be inflated with air and the cuff's pressure will be adjusted to 70 mmHg using a cuff pressure manometer. the device will be lubricated well on both sides, head and neck were placed in neutral position, the proximal firmer part of the device will be compressed between the thumb and two fingers and advanced toward hard and soft palate, the tab will be pulled slightly if needed to increase curvature of the device for better fitting, the device will be advanced till resistance felt.
Study NCT03946696 — intervention group
Intervention type: OTHER
Intervention: Interactions with therapy-animals
Description: How people interact with humans and non-humans animals during and outside visits from therapy-animal teams.
Study NCT05116800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
Study NCT05116800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
Study NCT05116800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
Study NCT05381246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, and pericardial meridian 6th point (PC6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected three different points will also be applied to the other extremity, a total of 18 minutes of compression will be applied to each point, provided that it is three minutes.
Study NCT05381246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: In the reiki group, the crown chakra (top of the head), the forehead chakra (above the forehead), the throat chakra (above the throat), the heart chakra (the middle of the chest), the solar plexus (under the chest, above the navel), the sacral chakra (below the navel) and the root chakra (above the coccyx) will be applied to the region of the 7 chakra points on.In the reiki group, the reiki application time will take 21 minutes on average.
Study NCT06528275 — intervention group
Intervention type: OTHER
Intervention: Health promotion intervention
Description: Health promotion intervention with activites linked to nutrition, and distribution of baskets of fresh fruits and vegetables
Study NCT05355350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin / Tazobactam Injection
Description: 4.5 grams QID
Study NCT05355350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 1 gram TID
Study NCT06501287 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Postprandial triglyceride
Description: impact of postprandial triglyceride level on coronary atherosclerosis
Study NCT06131164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing Exercise Group
Description: The subjects in this group will perform Diaphragmatic Breathing Exercise Group
Study NCT06131164 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Extension Exercise Group
Description: The subjects in this group will perform Thoracic Extension Exercise Group
Study NCT06083922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1, 8 and 15, Cycles 1-8
Study NCT06083922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Days 1,8,15, Cycles 1-8, Days 1,15 Cycles 9+
Study NCT06083922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Days 1,2,8, 9,15,16, 22, 23, Cycles 1-8
Study NCT06083922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Days 1,8,15,22, Cycles 1-2, Days 1,15 Cycles 3-6, Day 1 Cycles 7+
Study NCT04989101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nigella
Description: The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.
Study NCT06418139 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention added by the study
Study NCT04798651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
Study NCT04798651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cerebro-spinal fluid
Description: 1 ml of cerebro-spinal fluid
Study NCT03917407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DUR-928 (Moderate AH)
Description: A total of no more than two doses of DUR-928 will be given, with 72 hrs between each dose. A second dose of the assigned study treatment (test drug) will be repeated 3 days after Dose 1 to patients who are still hospitalized. If a patient meets the discharge criteria prior to Day 4, the patient will receive only one dose of DUR 928.~Patients of Part A (MELD 11-20) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1A: 30 mg of DUR-928in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2A: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3A: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.
Study NCT03917407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DUR-928 (Severe AH)
Description: Dose escalation to the next cohort will be determined after review of safety, tolerability and pharmacokinetic data of the previous cohort. Dose escalation for Part B will follow the same requirements as for Part A. The dose levels for Part B are planned to be the same as Part A.~Patients of Part B (MELD 21-30) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1B: 30 mg of DUR-928 in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2B: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3B: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion More details on preparation and administration of study drug will be provided in the Investigation Product Manual for this study.
Study NCT05291169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omeza® OCM™
Description: Omeza® OCM™ is a wound care matrix comprised of coldwater fish peptides (device) and cod liver oil (drug).~OCM™is supplied in a sterile single use vial.
Study NCT06344845 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-PBB3 PET/CT scan
Description: Patients with suspected neurodegeneration underwent PET/CT scan after injection of 370MBq (10 mCi)18F-FDG to observe for TAU deposition.
Study NCT05429736 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motor Skill Training (MST)
Description: During MST participants will perform a series of 6 motor skill exercises designed to challenge balance, lower extremity coordination, agility, and speed. Five of these activities will be performed while standing to promote upright control and one activity will be performed while seated (alternating toe-tapping) to provide opportunity for active recovery. Participants will perform each exercise for one minute each, until 4 cycles of the circuit have been completed (approximately 45 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). During MST, participants will wear a chest-worn heart rate monitor to ensure that the optimal HRR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
Study NCT05429736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Skill Training (MST)
Description: During MST participants will perform a series of 6 motor skill exercises designed to challenge balance, lower extremity coordination, agility, and speed. Five of these activities will be performed while standing to promote upright control and one activity will be performed while seated (alternating toe-tapping) to provide opportunity for active recovery. Participants will perform each exercise for one minute each, until 4 cycles of the circuit have been completed (approximately 45 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). During MST, participants will wear a chest-worn heart rate monitor to ensure that the optimal HRR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
Study NCT05429736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Stimulation (TSS)
Description: TSS will be delivered using a commercially available neuromuscular electrical stimulator. The active electrode will be positioned directly over the spine at the T11/T12 spinous interspace, and the reference electrode will be positioned over the umbilicus. Stimulation intensity will be gradually increased until paresthesia of the lower legs and feet is achieved or to the highest level each participant can tolerate. Stimulation will be delivered for a total duration of 30 min after paresthesia/ maximum tolerability is reached.
Study NCT06317129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic gastric restriction and biliodigestive diversion
Description: The BariTon™ is endoscopically implanted.
Study NCT06087627 — intervention group
Intervention type: DRUG
Intervention: Dupilumab SAR231893 (REGN668)
Description: Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
Study NCT04909983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DPLX-PT1
Description: A polymer skin patch for occlusional therapy
Study NCT04909983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: Standard of care
Study NCT06193551 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ovitex LPR
Description: Robotic assisted laparoscopic repair of hiatal hernia using permanent sutures with Ovitex mesh as reinforcement.
Study NCT05707039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open kinetic chain exercises
Description: In open chain exercises extremities are free to move and there is no weight bearing.
Study NCT05707039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain exercises
Description: In closed kinetic chain exercises extremities are fixed and weight bearing is done.
Study NCT05511077 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet
Description: Intervention products consist of two different oat products, one solid and one liquid. The content of oat in the products differs.
Study NCT05520892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous immunoglobulin
Description: To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia
Study NCT05520892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous immunoglobulin
Description: To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia
Study NCT05862506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Mile
Description: The intervention consisted of walking, jogging or running for \~ 15 min (\~ one mile) of exercise at a pace self-selected by each individual child, outside the school buildings during recess time, three times a week during 10 weeks. Children were instructed to maintain active for the full 15 min and, if necessary, to stop for resting only occasionally.
Study NCT04941170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Ultrasound-guided oblique subcostal transversus abdominis plane block will be performed in the supine position under strict aseptic precautions. placing a linear high-frequency ultrasound probe obliquely near the costal margin and xiphoid process On confirming the placement of the needle in the correct target space, 1 mL of 0.25% bupivacaine will be injected to hydro-dissect the fascia layer between the RA and TA. After confirming the separation of the transversus abdominis fascia plane, the remaining 19 mL of 0.25% bupivacaine will be administered, advancing the needle infero-laterally parallel to the subcostal margin. A similar procedure will be performed on the contralateral side of the abdomen with an injection of another 20 mL of 0.25% bupivacaine.
Study NCT04941170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Ultrasound-guided erector spinae plane block will be performed in the sitting position. T7 spinous process will be located To perform the block. The tip of the T7 transverse process will be then identified using the ultrasound probe that is placed in a transverse orientation The ultrasound transducer will then be placed in a longitudinal orientation 2-3 cm lateral to the midline in a longitudinal orientation to identify the hyperechoic line of the transverse process with its associated acoustic shadow. After local anaesthetic infiltration, the block needle will be inserted in a craniocaudal direction until contact will be achieved with the T 7 transverse process where the tip will lay in the inter-fascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle to confirm the proper needle position. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally.
Study NCT05439785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental floss/Interdental brush
Description: Initially plaque disclosing tablets were used to disclose plaque and plaque and bleeding scores will be recoded. After mechanical plaque debrided, instructions regarding the allocated interdental device given to the patient along with motivation to continue practicing good oral hygiene. After six weeks patients were recalled for reevaluation
Study NCT06174090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coronary bypass graft surgery video education
Description: It includes information about surgical process and handling issues within the first few days of surgery.